CGON (CG Oncology, Inc.) Forward P/E Multiple

Official company branding of CG Oncology (CGON)

The future of CG Oncology, Inc. (CGON) is based on an extreme dependence on a single platform targeting bladder cancer. The company's success relies on the commercialization of cretostimogene and FDA approval. The company's forward P/E ratio visualizes these expectations, and the value is currently held at 0.00. Business growth is supported by strategic engagement with scientific communities to create innovative immunotherapy.

CG Oncology - CGON Forward P/E Multiple (period 02/21/2024 - 11/18/2026)

Summary analytical data breakdowns for CG Oncology, Inc. (CGON)

- current price and projected stock value:
Fundamental company analysis:CG Oncology Inc
Brand item of CG Oncology Therapeutics

CG Oncology, Inc. (CGON) is currently in a phase of intensive investment in clinical trials, meaning the company's forward P/E reflects market expectations regarding the transition from capital burn to profitability. This indicator measures the cost per unit of projected earnings, demonstrating how the potential monopoly status of its bladder cancer therapy and low production costs create powerful operating leverage for capitalization.

Competitor analysis

Forward P/E Multiple ONC|HALO (Halozyme Inc.) - Future Price to Earnings Multiple|Forward P/E Multiple RVMD (revmed.com)|AAPG - Projected Price to Earnings|URGN: Projected Price to Earnings|BCAX - Forward P/E Multiple|Personalis Corp (PSNL) - Future Price to Earnings|Erasca Corp - Future Price to Earnings Multiple|DCTH (Delcath Systems Inc) - Forward P/E Multiple|Projected Price to Earnings Ratio Y-mAbs Therapeutics, Inc. YMAB|Forward P/E Multiple AURA|Projected Price to Earnings Candel Therapeutics, Inc. CADL|Forward P/E Multiple ARAY (Accuray, Inc.)|SELLAS Life Sciences - Future Price to Earnings|ACTU: Projected Price to Earnings|Citius Oncology, Inc. - Market Cap to Future Earnings Ratio|HURA (TuHURA Biosciences) - Projected Price to Earnings|TARA: Market Cap to Future Earnings Ratio|Projected Price to Earnings FATE|WHWK: Future Price to Earnings Multiple|Projected Price to Earnings TCRX (TScan Therapeutics Inc)|Market Cap to Projected Earnings Champions Oncology Inc|Forward P/E Multiple XBIT (XBiotech Inc.)|Future Price to Earnings Multiple CVM|OS Therapies Inc. - Forward P/E Multiple|RADX - Forward P/E Multiple|ARTV: Forward P/E Multiple|ANL: Market Cap to Future Earnings Ratio|Projected Price to Earnings VERU|TPST: Future Price to Earnings Multiple|Future Price to Earnings xiliotx.com (XLO)|Renovaro - Price to Future Earnings Ratio|Future Price to Earnings Mural Oncology MURA|KAPA - Projected Price to Earnings|OKUR - Future Price to Earnings|GDTC - Forward P/E Multiple|Curis, Inc. (CRIS) - Future Price to Earnings|Projected Price to Earnings Apollomics, Inc.|Projected Price to Earnings THAR|Price to Future Earnings Ratio ADVB (Advanced Biomed)|Projected Price to Earnings GNPX (Genprex, Inc)|CLDI: Price to Expected Earnings Ratio|Future Price to Earnings sunshinebiopharma.com SBFM|XBIO - Projected Price to Earnings|SLRX: Projected Price to Earnings|Purple Biotech - Market Cap to Future Earnings Ratio|American Oncology Network (AONC) - Future Price to Earnings|Price to Future Earnings Ratio BGNE|Projected Price to Earnings CKPT|Future Price to Earnings ELEV|Forward P/E Multiple ICAD|Forward P/E Multiple Ikena Oncology Inc. (IKNA)|Forward P/E Multiple NTBL (Notable Labs Ltd)|Market Cap to Projected Earnings Viracta Therapeutics (VIRX)|MOR: Projected Price to Earnings|NAYA (NAYA Bio) - Price to Future Earnings Ratio|AAPGV: Forward P/E Multiple